Replies to post #107924 on Biotech Values

[jb_118]

Well, MNTA essentially drafted the FDA requirements for approvability set forth in #msg-52582225 to coincide with MNTA’s patent estate on Lovenox characterization. So it would be a good bet that any approved product would be infringing MNTA’s patents.

So you're basically saying MNTA has a functional patent on generic lovenox?